相关实验视频

Updated: Jun 4, 2025

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

在T细胞急性淋巴细胞白血病中,切口抑制剂和BH3模拟剂

Ilaria Sergio¹, Claudia Varricchio², Federica Squillante¹

¹Department of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy.

International journal of molecular sciences

|December 17, 2024

概括

本综述探讨了针对Notch信号和Bcl-2蛋白来治疗T细胞急性淋巴细胞白血病 (T-ALL). 将这些策略结合起来,有望在T-ALL患者中克服治疗耐药性.

科学领域:

血液学血液学血液学
在瘤学瘤学.
分子生物学分子生物学

背景情况:

T细胞急性淋巴细胞白血病 (T-ALL) 是一种具有不良治疗结果的侵袭性癌症,特别是在复发/耐药病例中.
异常的Notch信号传递是T-ALL发育和对治疗的耐药性的关键驱动因素.
在T-ALL病变发生过程中,Notch信号与抗亡的Bcl-2家族蛋白之间的相互作用至关重要.

研究的目的:

审查最近针对T-ALL治疗直接准Notch受体的进展.
讨论验证的BH3模仿剂在T-ALL治疗中的应用.
评估Notch抑制和Bcl-2向T-ALL的联合治疗潜力.

主要方法:

对T-ALL.中Notch信号通路的当前文献的综述.
对研究玛分泌酶抑制剂 (GSIs) 和标抗体的研究分析.
对BH3模仿剂及其与Bcl-2家族蛋白质相互作用的研究进行了审查.

主要成果:

缺口抑制策略,包括GSI和受体/连接体抗体,是新兴的治疗选择.
BH3模仿剂提供了一种经过验证的方法来向抗亡蛋白.
临床前数据表明,当将Notch抑制与BH3模仿剂相结合时,会产生协同效应.

结论:

准Notch信号和Bcl-2蛋白质代表了对T-ALL的有前途的个性化医疗方法.
联合抑制Notch和Bcl-2通路可能克服治疗耐药性.
需要进一步的临床研究来验证这些结合策略在T-ALL治疗中的有效性.

关键词:

BH3模仿的是 BH3 的模仿.Bcl-2家族蛋白质中的一种.没有口,没有口.缺口抑制剂缺口抑制剂缺口抑制剂这就是T细胞白血病.

更多相关视频

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Notch Signaling Pathway

Notch Signaling Pathway

The Notch signaling pathway is a major intracellular signaling pathway that is highly conserved over a broad spectrum of metazoan species. It stands unique from other intracellular signaling mechanisms in animals because notch protein itself acts as the receptor as well as the primary signaling molecule.
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...